Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults-Reference-Cited by-同舟云学术

Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults

Published:2022-10-18 Issue:10 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Shimizu Ryosuke¹^ORCID,Sonoyama Takuhiro²,Fukuhara Takahiro³,Kuwata Aya³,Matsuo Yumiko¹,Kubota Ryuji¹

Affiliation:

1. Shionogi & Co., Ltd., Clinical Pharmacology & Pharmacokinetics, Osaka, Japan

2. Shionogi & Co., Ltd., Medical Science Department, Osaka, Japan

3. Shionogi & Co., Ltd., Clinical Research Department, Osaka, Japan

Abstract

Ensitrelvir is a novel selective inhibitor of the 3C-like protease of SARS-CoV-2, which is essential for viral replication. This phase 1 study of ensitrelvir assessed its safety, tolerability, and pharmacokinetics of single (part 1, n = 50) and multiple (part 2, n = 33) ascending oral doses.

Funder

Shionogi

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00632-22

Reference22 articles.

1. WHO. 2020. WHO Coronavirus Dashboard. https://covid19.who.int/. Retrieved 12 March 2022.

2. COVID ‐19 acute respiratory distress syndrome ( ARDS ): clinical features and differences from typical pre‐ COVID ‐19 ARDS

3. COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses